Hemab Therapeutics

Denmark - Copenhagen, Capital Region

• 22/02/2023
• Series B
• $135,000,000

Hemab Therapeutics ApS is an emerging biotech company supported by Novo Holdings A/S with the aim of developing novel treatments for rare and underserved bleeding disorders. Based in Copenhagen, the company is led by a team of drug developers and scientists with deep expertise in haemophilia. Hemab has exclusive licences to state-of-the-art antibody technologies from both Novo Nordisk A/S and Genmab A/S.

Related People

Benny SorensenFounder

United States - Cambridge, Massachusetts

Experienced patient centric Biotechnology Executive with demonstrated translational research, early- intermediate- and late stage clinical development experience. Strong entrepreneurial profile and successful track record of building lean high-performing R&D organizations. Excellent presentation and discussion skills. Extensive pharma-, biotech- and clinical academic high profile network.

LinkedIn https://www.linkedin.com/in/benny-sorensen-7227302/